2019冠状病毒病相关血栓形成的研究进展  

Research progress of COVID-19-associated thrombosis

作　　者：沈国民[1] 沈滟[1] 杨海平[2] SHEN Guo-min;SHEN Yan;YANG Hai-ping(Henan International Joint Laboratory of Thrombosis and Hemostasis,School of Basic Medical Science,Luoyang 471023,China;Department of Hematology,First Affiliated Hospital,Henan University of Science and Technology,Luoyang 471023,China)

机构地区：[1]河南科技大学基础医学院,河南省血栓与止血国际联合实验室,河南洛阳471023 [2]河南科技大学第一附属医院血液科,河南洛阳471023

出　　处：《中国病理生理杂志》2021年第12期2286-2292,共7页Chinese Journal of Pathophysiology

基　　金：国家自然科学基金资助项目(No.81770140,No.82170133);河南省科技攻关项目(No.212102310629,No.212102310877)。

摘　　要：新型冠状病毒肺炎(2019冠状病毒病,coronavirus disease 2019,COVID-19)是由新型冠状病毒(严重急性呼吸综合征冠状病毒2,severe acute respiratory syndrome coronavirus 2,SARS-Co V-2;简称新冠病毒)引起的一种呼吸系统传染病,是目前人类面临的最大的公共卫生问题。Coronavirus disease 2019(COVID-19)is a respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Clinical data have indicated that COVID-19 is associated with a significant risk of thrombotic complications ranging from microvascular thrombosis,venous thrombosis,and arterial thrombosis.The evidence to date supports that the thrombotic complications are caused by immunothrombosis,which culminates in the initiation of innate immune responses due to SARS-CoV-2 invading endothelial cells,and subsequent endothelial inflammation,complement activation,thrombin generation,and platelet and leukocyte recruitment.Several antithrombotic drugs have been explored as potential therapies to prevent COVID-19,and the antithrombotic therapy will hopefully improve outcomes for patients with COVID-19-associated thrombosis.

关 键 词：新型冠状病毒肺炎/2019冠状病毒病 新型冠状病毒 免疫血栓形成 固有免疫 血栓并发症 

分 类 号：R563.14[医药卫生—呼吸系统] R363[医药卫生—内科学]